An advanced calcium scoring application developed by the Scottish firm Voxar has cleared the FDA. Voxar Calscreen 2.1 is designed to detect, quantify, and report the presence of calcium plaque in the coronary arteries. It complements the company's
An advanced calcium scoring application developed by the Scottish firm Voxar has cleared the FDA. Voxar Calscreen 2.1 is designed to detect, quantify, and report the presence of calcium plaque in the coronary arteries. It complements the company's flagship Plug n View 3D and Voxar Colonscreen products. The package automates the identification of calcified plaques in the coronary arteries and calculates the calcium score, providing the basis for assessing potential risk and managing associated coronary heart disease before symptoms arise. Calscreen 2.1 works with electron-beam tomography scanners and multislice or helical CTs. The package, which runs on a standard PC, automatically highlights calcified regions in red as part of multiplanar reformatted (MPR) and 3D views of the heart.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.